RAPT
RAPT Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$58.01
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 1.5M | 3.8M |
| Cost of Revenue | 200.0K | — | — | — | — |
| Gross Profit | (200.0K) | — | — | 1.5M | 3.8M |
| Operating Expenses | |||||
| R&D Expense | 82.9M | 107.2M | 101.0M | 67.1M | 57.0M |
| SG&A Expense | 29.8M | 28.9M | 26.1M | 20.2M | 16.0M |
| General & Admin Expense | 29.8M | 28.9M | 26.1M | 20.2M | 16.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (200.0K) | — | — | — | — |
| Total Operating Expenses | 112.4M | 136.1M | 127.1M | 87.3M | 73.0M |
| Cost and Expenses | 112.6M | 136.1M | 127.1M | 87.3M | 73.0M |
| Operating Income (EBIT) | (112.6M) | (136.1M) | (127.1M) | (85.8M) | (69.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 7.0M | 6.2M | 10.3M | 2.0M | 5.0K |
| Non-Operating Income (excl Interest) | (3.7M) | — | — | — | — |
| EBT (Pre-Tax Income) | (105.6M) | (129.9M) | (116.8M) | (83.8M) | (69.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (105.6M) | (129.9M) | (116.8M) | (83.8M) | (69.2M) |
| Earnings from Cont. Ops | (105.6M) | (129.9M) | (116.8M) | (83.8M) | (69.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (105.6M) | (129.9M) | (116.8M) | (83.8M) | (69.2M) |
| Per Share | |||||
| Basic EPS | ($11.07) | ($25.49) | ($24.37) | ($20.61) | ($20.21) |
| Diluted EPS | ($11.07) | ($25.49) | ($24.37) | ($20.61) | ($20.21) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.38 | $1.11 |
| Shares | |||||
| Basic Shares Outstanding | 27.0M | 5.1M | 4.8M | 4.1M | 3.4M |
| Diluted Shares Outstanding | 27.0M | 5.1M | 4.8M | 4.1M | 3.4M |
| Profitability Metrics | |||||
| EBITDA | (108.0M) | (134.9M) | (125.8M) | (84.7M) | (68.2M) |
| D&A | 944.0K | 1.2M | 1.2M | 1.0M | 996.0K |
| EBIT | (109.0M) | (136.1M) | (127.1M) | (85.8M) | (69.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025